Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALG 1007

Next Previous
Drug Profile

ALG 1007

Alternative Names: ALG-1007

Latest Information Update: 23 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allegro Ophthalmics
  • Class Eye disorder therapies; Peptides
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 23 Feb 2022 ALG 1007 is still in phase II trial for Dry eyes in USA (Ophthalmic, Drops) (Allegro Ophthalmics pipeline, February 2021)
  • 24 Jul 2021 US FDA approves IND application for ALG 1007 for phase IIb/III trial in Dry eyes
  • 24 Jul 2021 Allegro Ophthalmics plans a phase IIb/III trial for Dry eys in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top